Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lactobacillus plantarum LPL28** is a specific probiotic strain of Lactobacillus plantarum, originally isolated from fermenting soybeans in 2011[3]. It is characterized by its beneficial effects on oral health, notably in reducing *Streptococcus mutans*, improving oral microbial flora, increasing secretory IgA in saliva, and supporting the immune response[3][4][6]. LPL28 is distinguished for its strong tolerance to acidic and bile environments, indicating robust survivability through the gastrointestinal tract[3]. Clinical research highlights its applications as a food additive and in oral lozenge formulations to promote oral health, relieve gastrointestinal symptoms, and decrease the incidence of oral infections, constipation, gastroesophageal reflux, and upper respiratory tract symptoms[2][4][6]. The strain has demonstrated superior antipathogenic and bactericidal activities against major oral pathogens (*S. mutans*, *A. actinomycetemcomitans*, *P. gingivalis*) in both postbiotic (heat-killed and fermentation product) and viable forms[2]. Its mechanism of action involves microbiome modulation, pathogen inhibition by antimicrobial metabolite production, and immunostimulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus plantarum LPL28.